Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality
Diabetes & Metabolism Journal · 01.01.2025 · 49 (1) · 80-91
DOI: 10.4093/dmj.2024.0042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 01.01.2025. Verfasst von Rosa Oh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Diseases, Fatty Liver. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Given the association between nonalcoholic fatty liver disease and metabolic risks, a new term, metabolic dysfunction- associated steatotic liver disease (MASLD) has been proposed. We aimed to explore the association between MASLD and all-cause, cause-specific mortalities.
Methods
We included individuals with steatotic liver disease (SLD) from the Korean National Health Insurance Service. Moreover, SLD was defined as a fatty liver index ≥30. Furthermore, MASLD, metabolic alcohol-associated liver disease (MetALD), and alcoholic liver disease (ALD) with metabolic dysfunction (MD) were categorized based on alcohol consumption and MD. We also analyzed all-cause, liver-, cancer-, hepatocellular carcinoma (HCC)- and cardiovascular (CV)-related mortalities.
Results
This retrospective nationwide cohort study included 1,298,993 individuals aged 40 to 79 years for a mean follow-up duration of 9.04 years. The prevalence of MASLD, MetALD, and ALD with MD was 33.11%, 3.93%, and 1.00%, respectively. Relative to the “no SLD” group, multivariable analysis identified that MASLD (adjusted hazard ratio [aHR], 1.28; 95% confidence interval [CI], 1.26 to 1.31), MetALD (aHR, 1.38; 95% CI, 1.32 to 1.44), and ALD with MD group (aHR, 1.80; 95% CI, 1.68 to 1.93) have a significantly higher risk of all-cause mortality. Furthermore, MASLD, MetALD, ALD with MD groups showed higher liver-, cancer-, and HCC-related mortality than “no SLD” group. While all-cause specific mortalities increase from MASLD to MetALD to ALD with MD, the MetALD group shows a lower risk of CV-related mortality compared to MASLD. However, ALD with MD group still have a higher risk of CV-related mortality compared to MASLD.
Conclusion
SLD is associated with an increased risk of all-cause, liver-, cancer-, HCC-, and CV-related mortalities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, Korea.
Zitieren
APA
Oh, R., Kim, S., Cho, S. H., Kim, J., Lee, Y. B., Jin, S. M., Hur, K. Y., Kim, G., & Kim, J. H. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality. Diabetes & Metabolism Journal, 49(1), 80-91. https://doi.org/10.4093/dmj.2024.0042
Vancouver
Oh R, Kim S, Cho SH, Kim J, Lee YB, Jin SM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality. Diabetes & Metabolism Journal. 2025;49(1):80-91. doi:10.4093/dmj.2024.0042
BibTeX
@article{Oh2025,
author = {Oh, Rosa and Kim, Seohyun and Cho, So Hyun and Kim, Jiyoon and Lee, You-Bin and Jin, Sang-Man and Hur, Kyu Yeon and Kim, Gyuri and Kim, Jae Hyeon},
title = {Metabolic Dysfunction-Associated Steatotic Liver Disease and All-Cause and Cause-Specific Mortality},
journal = {Diabetes & Metabolism Journal},
year = {2025},
volume = {49},
number = {1},
pages = {80--91},
doi = {10.4093/dmj.2024.0042}
}
EUVIMED